Dr. Robert Wenham, MD

• Gynecologic Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Duke University Medical Center

  Fellowship Hospital, 2004

• Brigham And Womens Hospital And Massachusetts General Hospital

  Residency Hospital, 2001

• Brigham And Womens Hospital And Massachusetts General Hospital

  Internship Hospital, 1998

• University Of Texas Southwestern Medical Center

  Medical School, 1997

• Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T-cells, 2022-04-14

• IgA transcytosis and antigen recognition govern ovarian cancer immunity, 2021-02-03

• "I think that a brief conversation from their provider can go a very long way”: Patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer, 2020-09-25

• Prognostic features of endometrial cancer metastasis to the central nervous system, 2022-08-26

• Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomes, 2021-11-23

• What is the Role of Retroperitoneal Exploration in Optimally Debulked Stage IIIC Epithelial Ovarian Cancer?: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Study, 2016-11-16

• Does Adjuvant Chemotherapy Dose Modification Have an Impact On the Outcome of Patients diagnosed with Advanced Stage Ovarian Cancer? An NRG Oncology/Gynecologic Oncology Group Study, 2018-08-19

• Illuminating the Numbers: Integrating Mathematical Models to Optimize Photomedicine Dosimetry and Combination Therapies, 2019-04-02

• Lagged Relationships Among Sleep Disturbance, Fatigue, and Depressed Mood During Chemotherapy, 2013-02-25

• New therapies for advanced, recurrent, and metastatic endometrial cancers, 2017-12-02

• Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance, 2015-12-28

• Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers, 2017-06-08

• Gene expression signature-based prediction of lymph node metastasis in patients with endometrioid endometrial cancer, 2017-11-11

• Implementing Personalized Medicine in a Cancer Center, 2011-10-25

• Right Place, Right Time: Preferences of Women with Ovarian Cancer for Delivery of CAM Education, 2015-08-31

• Patterns and Predictors of Genetic Referral among Ovarian Cancer Patients at a National Cancer Institute Comprehensive Cancer Center, 2019-11-24

• Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study, 2017-02-10

• Relationships among Inflammatory Biomarkers and Self-Reported Treatment-Related Symptoms in Patients Treated with Chemotherapy for Gynecologic Cancer: A Controlled Comparison, 2023-06-29

• A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube, 2014-01-27

• Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: A NRG/Gynecologic Oncology Group Study, 2017-10-14

• BAD phosphorylation determines ovarian cancer chemo-sensitivity and patient survival, 2011-08-17

• Relationships among Inflammatory Biomarkers and Objectively Assessed Physical Activity and Sleep during and after Chemotherapy for Gynecologic Malignancies, 2023-07-30

• Utilizing the Radiosensitivity Index (RSI) to Predict Pelvic Failure in Endometrial Cancer Treated with Adjuvant Radiotherapy, 2019-11-20

• A phase I trial of dasatinib, a Src-family kinase Inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer, 2012-07-26

• Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” [Gynecol. Oncol. 151 (2018) 18-23], 2018-10-23

• Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma, 2018-12-18

• The BCL2 Antagonist of Cell Death pathway influences endometrial cancer cell sensitivity to cisplatin, 2011-10-26

• Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity, 2014-04-24

• Olfactory Receptor OR2H1 is an effective target for CAR T cells in human epithelial tumors, 2022-07-05

• Prospective Follow-up of Quality of Life for Participants Undergoing Risk-Reducing Salpingo-Oophorectomy or Ovarian Cancer Screening in GOG-0199: An NRG Oncology/GOG Study, 2019-11-21

• Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study, 2017-09-19